RecruitingNCT06195150
Overtaking Intra and Inter Tumoral Heterogeneity In Von Hippel-Lindau Related Renal Cancer
Sponsor
IRCCS San Raffaele
Enrollment
3 participants
Start Date
Nov 8, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
The goal of this study is to comprehensively map intra and inter tumor heterogeneity of ccRCC in VHL patients through the use of imaging, molecular biology and genomics techniques.
Eligibility
Min Age: 18 YearsMax Age: 99 Years
Inclusion Criteria2
- VHL syndrome
- Presence of at least 3 kidney tumors larger that 3cm to be surgically removed
Exclusion Criteria3
- Absence of VHL
- Quantity of kidney tumors < 3
- Absence of surgery performance
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OTHERBlood collection
15ml of blood are harvested before surgery
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06195150
Related Trials
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
NCT0722741547 locations
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
NCT06661720409 locations
Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC
NCT068633112 locations
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
NCT0553614129 locations
An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma
NCT074696831 location